Hello, Fool! | Login | Signup | My Fool
Dec 1, 2008 6:57 PM ET | Feedback | Site Changes | Help
The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies.
View All Commentary (BIIB)
Recs
KingPortu (67.55) Submitted: 10/29/07 2:36 PM : Start Price: $74.07 BIIB Score: 0.68
Not much to look at. Negative earnings, neg FCF, balance sheet is mediocre... Biotech sucks lately. What happened?
Report this Post Replies: 0 | Reply | Permalink
Oops! There appears to be a problem with your comment. Check to see if there's something you left out.
Terms & Conditions
RSS Headlines
Fool UK